Effect of BMY-28100, a new cephalosporin, on Staphylococcus aureus nasal carriageQuantitative Health Sciences Publications and Presentations
UMMS AffiliationDepartment of Quantitative Health Sciences
Medical Subject HeadingsAdult; Carrier State; Cephalosporins; Humans; Male; Nasal Cavity; Staphylococcal Infections; Staphylococcus aureus
AbstractIn order to examine the in vivo activity of BMY-28100, serial quantitative nasal cultures were taken from 52 nasal carriers of Staphylococcus aureus following administration of the antimicrobial. Nasal carriage rates and mean log titers decreased significantly during (days 2-4 and 5-8) and following (days 1-2 and 6-7) treatment. No change in antibiotic sensitivities was noted in follow-up isolates, and the MIC90 remained at 2mcg/ml. BMY-28100 demonstrated good in vivo activity against Staphylococcus aureus.
Rights and PermissionsCitation: Eur J Clin Microbiol. 1987 Dec;6(6):679-81.
Related ResourcesLink to Article in PubMed
Citation InformationR. L. Atmar, M. L. Allen, J. Freiman, Catarina I. Kiefe, et al.. "Effect of BMY-28100, a new cephalosporin, on Staphylococcus aureus nasal carriage" Vol. 6 Iss. 6 (1987) ISSN: 0722-2211 (Linking)
Available at: http://works.bepress.com/catarina_kiefe/51/